Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yishen Tiaogan formula is a Traditional Chinese Medicine (TCM) herbal formulation developed by Longhua Hospital, Shanghai University of Traditional Chinese Medicine. It is primarily investigated for the treatment of bone metastases in patients with breast cancer. The formula is designed to be used as an adjuvant therapy alongside standard postoperative regimens. Its therapeutic goals include improving objective response rates, enhancing disease control, modulating bone metabolism, and alleviating pain and other TCM-related symptoms. By targeting the Kidney (Yishen) and Liver (Tiaogan) systems in TCM theory, it aims to improve the quality of life and safety outcomes for breast cancer patients experiencing skeletal complications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yishen Tiaogan formula.